The global bleeding disorders treatment market size was worth USD 15.16 billion in 2023 and is forecasted to be worth USD 22.25 billion by 2028, growing at a CAGR of 7.98% between 2023 to 2028.
A bleeding disorder is a medical condition that is interfered with by blood clotting, which prevents the blood clot from forming. The common bleeding disorders are hemophilia, platelet disorders, Von Willebrand diseases, and others. Bleeding disorders can cause both internally and externally. Externally is blood flows out from the body when an injury happens. Internal bleeding occurs when the blood continues to flow under the skin like a brain clot. These kinds of issues arise in bleeding disorders. Haemophilia is one of the most occurring bleeding diseases where the blood doesn’t clot out. Von Willebrand disease occurs in women majorly.
In general, the bleeding disorders treatment includes the drugs that help treat and manage the bleeding disorder. It may result in harmful bleeding and blood clotting, and coagulation.
The treatment includes new frozen plasma, iron supplements, and antifibrinolytic drugs. This bleeding disorder can also be hereditary, lack vitamin K deficiency, reduce red blood cells, and use certain drugs that cause side effects.
Y-O-Y growth in the number of bleeding disorder cases and advancements in treatments primarily drive the global bleeding disorder treatment market growth.
The growing number of patients with bleeding disorders is a significant driver of the bleeding disorder treatment market. More than 1,125,000 men worldwide suffer from the genetic bleeding disorder, with 418,000 suffering from a moderate form of the often-undiagnosed disease. Haemophilia is the most prevalent condition, affecting over 195 thousand patients in 2019, and 80 thousand people were living with von Willebrand disease, Statista says. There are over 18 thousand patients with hemophilia and over 12 thousand with von Willebrand disease in the United States alone. According to the CDC, Von Willebrand disease (VWD) affects about 1% of the general population. On the other hand, women are particularly targeted by Von Willebrand disease due to their menstrual cycle. This large pool of patients is being treated with some method of treatment; thus, the market for bleeding disorder treatment has been growing.
Another factor driving the bleeding disorder treatment market is advancements in treatment by businesses and governments.
Many businesses and scientific institutions have been trying to find new medicines and strengthen existing medications that make many patients aware of treatment and increase the adoption rate. St. Jude's physicians and experts have been developing and improving therapies for children with bleeding disorders for over 50 years. They work with a federally designated Hemophilia Rehab Center and children's treatment services around the country. In addition, researchers at Children's Hospital of Philadelphia have created a theoretically safer and more efficient gene therapy vector for bleeding disorders, focusing on sickle cell disease and beta-thalassemia. Many replacement drugs have now been developed with simpler administration methods, lower immunogenicity, greater potency, and longer half-lives. Bioengineering advances have been assisting in treating bleeding disorders for the past 5 years. These advancements increase the bleeding disorder treatment market growth.
High costs associated with the treatments are expected to limit the global bleeding disorder treatment market growth.
However, the high cost of treatment is a significant impediment to the bleeding disorder treatment market. Daily outpatient appointments, hospitalization, and lab studies entail high costs that are unaffordable for middle-income countries such as Asia and Africa; thus, the development of bleeding disorders treatments in those regions is stagnant. Furthermore, a shortage of clinicians in emerging and underdeveloped nations and an unfavorable reimbursement situation impede the bleeding disorder treatment market.
Impact of COVID-19 on the global bleeding disorders treatment market:
The COVID-19 outbreak deemed a pandemic by WHO on March 11, 2020, has affected over 38 million people worldwide. Unfortunately, the healthcare system is unprepared for this situation. Many organizations are trying to discover a vaccine, but people must learn to deal with this coronavirus disease for the time being. This coronavirus may affect various organs and tissues in the body, including the blood. Any individuals who have been treated with SARS-CoV-2 experience irregular blood clotting. According to the evidence, COVID-19 creates a distinct, deeply prothrombotic environment that leads to arterial and venous thrombosis. As a consequence, during covid – 19 cases, the need for bleeding disorder treatment has risen.
Furthermore, covid – 19 affects the many clinical trials being conducted for the treatment of blood disorders. Since both hospitals are concentrated on coronavirus cases, often patients with bleeding disorders terminate their hospital appointments. In addition, hospitals canceled or delayed replacement treatments of hemophilia. Besides that, because of the travel ban and lockdown imposed by the pandemic, the supply chain of bleeding disorder medications or products has been disrupted. As a result, in this pandemic situation, bleeding disorder treatment is experiencing poor demand expansion.
Market Size Available
2022 to 2028
2023 to 2028
By Drug Class, Type, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
This research report on the global bleeding disorders treatment market has been segmented and sub-segmented based on drug class, type, and region.
Bleeding Disorders Treatment Market - By Drug Class:
Recombinant Coagulation Factor Concentrates
Plasma Derived Coagulation Factor Concentrates
Based on the drug class, the recombinant coagulation factor concentrates segment is to grow the fastest in the mentioned forecast period. Because of the increased R&D in this market and the increasing focus of pharmaceutical companies on recombinant products.
Bleeding Disorders Treatment Market - By Type:
Bleeding Disorders Treatment Market - By Region:
The Middle East and Africa
Geographically, North America accounts for the lion's share in the global bleeding disorders treatment market during the forecasting period. Due to the initial stage adoption of developed medical technologies, the market in this region is the rapid ongoing development of companies operating into drugs. As per the Hemophilia Federation of America, more than 20,000 people are affected with Hemophilia, and accurately 1% of the population is suffering from Von Willebrand Disease (VWD). In the North American market, the United States is forecasted to rule the market, followed by Canada. Factors such as the high incidences of bleeding disorders integrated with favorable reimbursement and insurance policies favor the U.S. bleeding disorders treatment market growth. The Canadian bleeding disorder treatment market is expected to have a healthy growth rate during the forecast period.
The European market is right next to North America to lead the majority of the global market share. It is forecasted to grow at an impressive growth rate during the forecast period. Companies such as Bayer AG(Germany) and Grifols SA(Spain) are currently accounting majority of the European market share. In 2018, the European Association for Haemophilia and Allied Doctors formed a working group on women and bleeding disorders and received approval for the proposal. The primary goal of this group is to bring awareness among healthcare providers and understand the needs of women with bleeding disorders. The German bleeding disorders treatment market is projected to lead the European market during the forecast period. Active initiatives by the key market participants to increase awareness and new product launches are some of the factors helping the market to grow. For Instance, On December 05, 201, Bayer AG announced the collaboration with the Children's Hospital for three years with an agenda to discover and develop small molecules for Hemophilia A and B.
However, the Asia-Pacific market is rapidly growing and is expected to showcase a remarkable CAGR during the forecast period. Factors such as growing economies, increasing health regulations, and rising awareness of bleeding disorders are majorly promoting the APAC market. The Chinese bleeding disorders treatment market is forecasted to account for most of the share in the APAC market during the forecast period. The easy availability of affordable test kits and the sprouting pharma sector are to help the Chinese market during the forecast period. The Indian bleeding disorders treatment market is estimated to showcase a lucrative growth rate during the forecast period. India's government takes few measures in constructing the required healthcare infrastructure to increase awareness regarding bleeding disorders and easily accessible medication for treating such conditions.
The Latin American regional market is expected to have a steady growth rate during the forecast period. Factors such as the rising R&D activities and growing pharmaceutical companies focus on developing the medications are expected to favor the Latin American market. The Brazilian market is forecasted to account significant share in the Latin American market.
The Middle East African market for bleeding disorders treatment is said to have a notable growth rate during the forecast period. The region provides high opportunities for the new entry of the companies as only a few competitors are present in the market.
KEY MARKET PARTICIPANTS:
Some of the promising companies operating in the global bleeding disorders treatment market profiled in the report are CSL Behring, Pfizer Inc., Novo Nordisk, Bayer AG, Biogen Inc., Shire Plc., Medline Plus, Janssen Global Services LLC, and Grifos SA.
These players depend on various strategies, such as product launches and product approvals. Many growth strategies undertaken by these players include mergers, acquisitions, and alliances. With the help of these strategies, players are increasing their market share in the bleeding disorder treatment market.
RECENT MARKET DEVELOPMENTS:
On February 10, 2020, Novo Nordisk made a public statement about the launch of ESPEROCT. It can be used in adults and children to control and treat bleeding during surgery.
On December 05, 2019, Bayer AG made a public statement that it will have a three-year collaboration with the children’s hospital. The development and discovery of small molecules to treat hemophilia A and B is the main motto of this collaboration.
On September 12, 2018, Shire Plc announced that the European Commission EU has received granted marketing authorization for VEYVONDI. It is the first Von Willebrand Factor used for the treatment of adults with bleeding and treats illness. It also helps in preventing bleeding during surgeries.
On 22 August 2018, The Royal College of Surgeons in Ireland (RCSI) and Bayer work together to create better therapies for patients with serious hemophilia. To ensure better and more efficient blood clotting in hemophilia patients, the clinical partnership may concentrate on customized therapies according to the seriousness of each patient's disease.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com